| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 南京 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
S82822-1mg一口价 |
98.00% | ￥150.00 ￥120.00 |
9 | - | - | - | - |
|
S82822-5mg一口价 |
98.00% | ￥255.00 ￥204.00 |
6 | - | - | - | - |
|
S82822-10mg一口价 |
98.00% | ￥425.00 ￥340.00 |
6 | - | - | - | - |
|
S82822-25mg |
98.00% | ￥680.00 |
6 | - | - | - | - |
|
S82822-50mg |
98.00% | ￥1140.00 |
5 | - | - | - | - |
|
S82822-100mg |
≥98% | ￥1610.00 |
货期：2-3天 | - | - | - | - |
|
| 产品描述： | Olodanrigan (EMA401, PD-126055, (S) PD-126055) 是一种高度选择性的、具有口服活性的外周限制性 angiotensin II type 2 receptor (AT2R) 拮抗剂。Olodanrigan 的镇痛作用可能涉及抑制增强 AngII/AT2R 诱导的 p38 和 p42/p44 MAPK 激活，从而抑制 DRG 神经元过度兴奋和 DRG 神经元的萌芽 | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 靶点： | AT2R;RAAS | ||||||||||||||||||||
| 体外研究： | EMA401 may act on paracrine/autocrine mechanisms at peripheral nerve terminals, or intracrine mechanisms, to reduce neuropathic pain signalling in AngII/NGF/TRPV1-convergent pathways | ||||||||||||||||||||
| 体内研究： | EMA401, a selective small molecule antagonist of the AT2R, results in a significant attenuation of theta power and increase in paw withdrawal latencies (PWL) in rats at day 14 after chronic constriction injury (CCI). | ||||||||||||||||||||
| 细胞实验： | Cell lines: rat DRG neurons Concentrations: 10, 100 nM Incubation Time: 30 min Method: 48 h after plating, duplicate dishes were treated with AngII (10 nM), AngII + EMA401 (10 and 100 nM respectively), 100 nM EMA401, NGF (100 ng/ml) or vehicle treated (control 0), for 30 min at 37 ℃, then fixed with 4% PFA for 30 min for immunostaining. | ||||||||||||||||||||
| 动物实验： | Animal Models: Adult male Sprague-Dawley (SD) rats with a unilateral chronic constriction injury (CCI) of the sciatic nerve Dosages: 1 mg/kg (i.v.); 10 mg/kg (p.o.) Administration: i.v.; p.o. | ||||||||||||||||||||
| 参考文献： | 1. Anand U, et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015 Jun 26;11:38. 2. Smith MT, et al.Small molecule angiotensin II type 2 receptor (AT₂R) antagonists as novel analgesics for neuropathic pain: comparative pharmacokinetics, radioligand binding, and efficacy in rats. Pain Med. 2013 May;14(5):692-705. | ||||||||||||||||||||
| 溶解性： | DMSO: ≥ 34 mg/mL | ||||||||||||||||||||
| 保存条件： | -20℃ | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京